EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classification

Claire Delbridge, Helen X Hou, Thomas Hielscher, Benedikt Wiestler, Chiara Negwer, Lena Schenck, Jan Peeken, Christian Diehl, Kai Borm, Sandro Krieg, Kaywan A Aftahy, Sophia M Leiss und 9 weitere

Journal of Neuro-Oncology · 2026-04 · 177 (2)

DOI: 10.1007/s11060-026-05508-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 23.03.2026. Verfasst von Claire Delbridge und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology and Pathology, School of Medicine, TU Munich, 81675, München, Germany. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technische Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Meningiomas (MNGs) occur in different histopathological subtypes. The WHO grading system classifies a subset as grade 2 and 3, indicating a more aggressive course. Recent advances in risk stratification introduces an integrated molecular-morphological score (IntS), offering improved risk prediction over the traditional WHO classification. This study aims to evaluate the prognostic utility of IntS in the context of the timing of adjuvant radiotherapy (RT).

Methods

This retrospective study analyzed 55 patients with histologically diagnosed WHO grade 2 and 3 MNG treated with adjuvant RT. Molecular analyses using Illumina 450k Human BeadChip and Illumina 850k EPIC stratified patients into 3 risk groups (low, intermediate and high) using an integrated model that combines WHO grading, Copy Number Variations (CNVs), and Methylation Families (MF).

Results

After 5 years a local failure-free survival (LFFS) rate of 0% in MF-malignant MNG contrasts with a LFFS rate of 77% and 58% in MF-benign and MF-intermediate MNG. A significant correlation between CNVs and LFFS was also observed in the adjuvant setting. The IntS model revealed distinct 5-year LFFS disparities across different risk categories, underscoring the impact of combined morphological and molecular characteristics on outcome.

Conclusion

The integration of DNA-methylation and CNV-profiles into the IntS unified risk score offer an enhanced prognostic differentiation of MNG patients. This approach shows a promising direction for guiding the optimal timing of adjuvant RT, offering a path toward more tailored treatment strategies for meningiomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsHumansFemalePrognosisRetrospective StudiesMaleNeoplasm GradingMiddle AgedWorld Health OrganizationAgedRadiotherapy, AdjuvantAdultDNA Copy Number VariationsDNA MethylationFollow-Up Studies

Stichwörter der Autor:innen

Adjuvant radiation therapyDNA methylationMeningiomasMolecular classificationRisk stratification

Autor:innen und Institutionen

  • Department of Neuropathology and Pathology, School of Medicine, TU Munich, 81675, München, Germany.
  • Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Straße 22, 81675, Munich, Germany. helen.hou@tum.de.
  • Department of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Neuroradiology, Klinikum rechts der Isar, TU Munich, 81675, München, Germany.
  • TranslaTUM, TU Munich, 81675, München, Germany.
  • Department of Neurosurgery, Klinikum rechts der Isar, TU Munich, 81675, München, Germany.

Förderung

  • Technische Universität München

Zitieren

APA

Delbridge, C., Hou, H. X., Hielscher, T., Wiestler, B., Negwer, C., Schenck, L., Peeken, J., Diehl, C., Borm, K., Krieg, S., Aftahy, K. A., Leiss, S. M., Schmidt-Graf, F., Mitsdörffer, M., Yakushev, I., Von Deimling, A., Gempt, J., Meyer, B., Combs, S. E., …, & Bernhardt, D. (2026). Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classification. Journal of Neuro-Oncology, 177(2). https://doi.org/10.1007/s11060-026-05508-4

Vancouver

Delbridge C, Hou HX, Hielscher T, Wiestler B, Negwer C, Schenck L, et al. Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classification. Journal of Neuro-Oncology. 2026;177(2). doi:10.1007/s11060-026-05508-4

BibTeX
@article{Delbridge2026,
  author = {Delbridge, Claire and Hou, Helen X and Hielscher, Thomas and Wiestler, Benedikt and Negwer, Chiara and Schenck, Lena and Peeken, Jan and Diehl, Christian and Borm, Kai and Krieg, Sandro and Aftahy, Kaywan A and Leiss, Sophia M and Schmidt-Graf, Friederike and Mitsdörffer, Meike and Yakushev, Igor and Von Deimling, Andreas and Gempt, Jens and Meyer, Bernhard and Combs, Stephanie E and Sahm, Felix and Bernhardt, Denise},
  title = {Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classification},
  journal = {Journal of Neuro-Oncology},
  year = {2026},
  volume = {177},
  number = {2},
  doi = {10.1007/s11060-026-05508-4}
}
Kostenlos starten →